eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2019
vol. 36
 
Share:
Send email
Share:
abstract:
Original paper

Ingenol mebutate treatment in actinic keratosis – clinical effectiveness and potential side effects

Aleksandra Lesiak
1
,
Anna Maćkowska
2
,
Igor A. Bednarski
1
,
Paweł Kolano
3
,
Irmina Olejniczak-Staruch
4
,
Anna Woźniacka
4
,
Joanna Sieniawska
4
,
Joanna Narbutt
1

  1. Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
  2. Student Research Group at Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
  3. Department of General and Oncological Surgery, Tomaszow Health Centre, Tomaszow Mazowiecki, Poland
  4. Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland
Adv Dermatol Allergol 2019; XXXVI (4): 468-471
DOI: https://doi.org/10.5114/ada.2019.87450
Online publish date: 2019/08/30
View full text Get citation
 
Introduction
Actinic keratosis is a common skin disease that occurs in response to prolonged exposure to ultraviolet radiation. This problem affects up to 60% of the population over 40 years of age. Actinic keratosis is considered to be a precancerous lesion leading to squamous cell carcinoma (SCC). The new therapeutic option for the treatment of actinic keratosis is ingenol mebutate gel (0.015%, 0.05%).

Aim
Retrospective evaluation of response and potential side effects of ingenol mebutate treatment in clinical practice.

Material and methods
Eight patients with actinic keratosis lesions on the face or scalp self-applied a 0.015% gel for 3 consecutive days on the 25 cm2 marked area. They were assessed at baseline and on day 4, 7, 14 and 57.

Results
All patients on day 57 presented a complete absence of AK lesions in the area of ingenol mebutate application. No adverse events were observed.

Conclusions
Our study shows that ingenol mebutate is highly efficacious field treatment for actinic keratosis.

keywords:

actinic keratosis, ingenol mebutate
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.